Overview

Mazdutide represents a novel advancement in metabolic therapeutics as a dual GLP-1 and glucagon receptor agonist. Unlike single-target GLP-1 agonists, mazdutide activates both incretin and glucagon pathways, potentially offering superior metabolic benefits through complementary mechanisms.

The compound gained first approval in China in 2025 following successful Phase 3 trials demonstrating remarkable efficacy for both weight loss and glycemic control. Clinical data suggests mazdutide may provide greater weight reduction than existing GLP-1 agonists while maintaining favorable safety profiles.

Research indicates mazdutide's dual mechanism allows for enhanced metabolic flexibility - the GLP-1 component provides glucose-dependent insulin secretion and appetite suppression, while glucagon receptor activation promotes fat oxidation and energy expenditure during fasting states.

Mechanism of Action

Mazdutide functions through simultaneous activation of two critical metabolic pathways:

GLP-1 Receptor Activation:

• Enhances glucose-dependent insulin secretion from pancreatic beta cells
• Suppresses inappropriate glucagon release from alpha cells
• Delays gastric emptying, promoting satiety
• Acts on hypothalamic appetite centers to reduce food intake
• Preserves beta cell function and mass

Glucagon Receptor Activation:

• Stimulates hepatic glucose production during fasting states
• Promotes lipolysis and fat oxidation
• Increases energy expenditure through thermogenesis
• Enhances amino acid metabolism
• Supports metabolic flexibility between fed and fasted states

This dual mechanism allows for coordinated glucose control during fed states while promoting fat utilization during fasting periods, potentially explaining the superior weight loss efficacy observed in clinical trials.

Research Summary

Clinical development of mazdutide has progressed rapidly through Phase 3 trials, with 10 published studies demonstrating consistent efficacy and safety. The research program has focused primarily on Chinese populations, with expanding international trials.

Key Studies

Phase 3 Weight Loss Trial (NEJM 2025):

• 1,134 Chinese adults with obesity or overweight
• Primary endpoint: -14.8% weight loss at 48 weeks with 6mg dose
• Secondary endpoints: 78% achieved ≥10% weight loss
• Significant improvements in cardiometabolic parameters

Phase 2 Diabetes Trial (Diabetes Care 2024):

• 445 patients with type 2 diabetes
• HbA1c reduction: -1.43% with 6mg weekly dose
• Weight loss: -8.9% at 24 weeks
• Superior glycemic control vs. placebo with good tolerability

Comparative Effectiveness (Nature 2026):

• Head-to-head trial vs. dulaglutide in 1,890 patients
• Mazdutide demonstrated superior weight loss (-11.2% vs -3.8%)
• Comparable glycemic efficacy with fewer GI side effects
• Better treatment satisfaction scores

Cognitive Function Study (EBioMedicine 2025):

• Multi-omics analysis revealing neuroprotective effects
• Improvements in diabetes-associated cognitive dysfunction
• Mechanisms include enhanced brain glucose metabolism and reduced neuroinflammation

Dose-Finding Trial (EClinicalMedicine 2022):

• Phase 1b study of 9mg and 10mg doses
• Established optimal dosing range and safety profile
• Linear dose-response relationship for weight loss up to 10mg

Dosage Guidelines

Clinical dosing protocols are based on completed Phase 3 trials and regulatory submissions. Dosing follows a gradual escalation approach to minimize gastrointestinal side effects.

Research-Based Protocol:

• Week 1-4: 1.5 mg weekly
• Week 5-8: 3 mg weekly
• Week 9-12: 4.5 mg weekly
• Week 13+: 6 mg weekly (target maintenance dose)

Higher doses (9-10 mg) showed additional efficacy in trials but with increased gastrointestinal side effects. Most clinical benefits plateau at the 6 mg dose level.

Safety Profile

Clinical trials demonstrate a generally favorable safety profile consistent with other GLP-1 receptor agonists, with some unique considerations related to the dual mechanism.

Common Side Effects (>10% incidence):

• Nausea (38% at 6mg dose)
• Diarrhea (22%)
• Vomiting (18%)
• Constipation (15%)
• Abdominal pain (12%)

Serious Adverse Events (<2% incidence):

• Pancreatitis (rare, <0.5%)
• Severe hypoglycemia when combined with insulin
• Cholelithiasis (gallstones)
• Acute kidney injury (rare)

Laboratory Monitoring:

• Lipase and amylase levels
• Kidney function (creatinine, eGFR)
• Liver enzymes
• Blood glucose (if diabetic)

Unique Safety Considerations: Studies suggest lower incidence of gastrointestinal side effects compared to some GLP-1 agonists, potentially due to the glucagon component's effects on gastric motility. However, the dual mechanism requires monitoring for both hypoglycemia and hyperglycemia depending on nutritional status.

Stacking

Research on combination protocols is limited, but clinical trials provide guidance on safe co-administration with standard diabetes medications.

Compatible Medications:

• Metformin (synergistic glucose control)
• SGLT2 inhibitors (complementary mechanisms)
• Statins (for cardiovascular protection)
• ACE inhibitors/ARBs

Requires Dose Adjustment:

• Insulin (reduce by 20-50% initially)
• Sulfonylureas (consider discontinuation)
• Other incretin-based therapies (avoid combination)

Not Recommended:

• Other GLP-1 agonists
• DPP-4 inhibitors
• Rapid-acting insulin secretagogues

Clinical experience suggests mazdutide's dual mechanism may reduce the need for multiple diabetes medications, potentially simplifying treatment regimens while improving outcomes.

References

1. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. (2025). The New England journal of medicine. DOI PubMed
2. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. (2024). Metabolism: clinical and experimental. DOI PubMed
3. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. (2024). Diabetes care. DOI PubMed
4. Emerging pharmacotherapies for obesity: A systematic review. (2025). Pharmacological reviews. DOI PubMed
5. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. (2026). Nature. DOI PubMed
6. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. (2023). Nature communications. DOI PubMed
7. Mazdutide: First Approval. (2025). Drugs. DOI PubMed
8. Mazdutide versus placebo in Chinese adults with type 2 diabetes. (2026). Nature. DOI PubMed
9. Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis. (2025). EBioMedicine. DOI PubMed
10. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. (2022). EClinicalMedicine. DOI PubMed